Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Jan;200(1):45-53.
doi: 10.1111/bjh.18479. Epub 2022 Oct 7.

Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study

Tamir Shragai  1   2 , Hila Magen  2   3 , Noa Lavi  4   5 , Moshe Gatt  6   7 , Svetlana Trestman  1 , Miri Zektser  8 , Chezi Ganzel  7   9 , Osnat Jarchowsky  2   10 , Tamar Berger  2   11 , Tamar Tadmor  5   12 , Merav Leiba  13   14 , Katrin Hertzog-Tzarfaty  15 , Netanel Horowitz  4   5 , Michael Shapira  16 , David Varssano  2   17 , Yoav Berger  18 , Shahar Frenkel  7   19 , Mark Krauthammer  2   17 , Irit Avivi  1   2 , Efrat Luttwak  1   2 , Yael C Cohen  1   2 ; Israeli myeloma study group
Affiliations
Multicenter Study

Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study

Tamir Shragai et al. Br J Haematol. 2023 Jan.

Abstract

Belantamab mafodotin, an immuno-conjugate targeting B-cell maturation antigen, showed single-agent activity in phase 1 and 2 studies, and was recently approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Real-world data and long-term follow-up are scarce. We conducted a multisite retrospective study aimed to assess safety and efficacy of belantamab mafodotin monotherapy administered via the GSK expanded access compassionate care programme. One-hundred and six RRMM patients were treated with belantamab mafodotin between July 2019 and March 2021. The median age was 69.4 years. Patients were heavily pretreated with a median of six (range 2-11) prior therapy lines. Major adverse effects included ocular toxicity (keratopathy 68.4%, grade ≥3: 40.5%; blurred vision 36.8%, grade ≥3: 6.3%), thrombocytopenia (27.4%, grade ≥3: 17.9%) and infections (11.3%, grade ≥3: 7.5%). Median follow-up time was 11.9 [95% confidence interval (CI) 10.0-13.8] months. Overall response rate was 45.5%. Median progression-free survival was 4.7 (95% CI 3.5-5.9) months in the entire cohort and 8.8 (95% CI 6.6-10.9) months among responders. Median overall survival was 14.5 (95% CI 9.5-19.6) months, and not reached for responders. To conclude, in a real-world setting, belantamab mafodotin monotherapy showed efficacy comparable with the prospective clinical trials, with a tolerable toxicity profile.

Keywords: immunotherapy; multiple myeloma; myeloma therapy.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests. Yael C. Cohen received honoraria from GSK, unrelated to this research. All other authors have no conflict of interests to declare.

Figures

FIGURE 1
FIGURE 1
(A) Progression‐free survival and overall survival. (B) Overall survival was significantly longer among patients achieving partial response or better. OS, overall survival; PFS, progression‐free survival. [Colour figure can be viewed at wileyonlinelibrary.com]
FIGURE 2
FIGURE 2
Progression‐free survival (A) and overall survival (B) were not statistically different among triple‐refractory and non‐triple‐refractory patients. [Colour figure can be viewed at wileyonlinelibrary.com]
See this image and copyright information in PMC

References

    1. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38‐targeted monoclonal antibody therapy. Leukemia. 2019. Sep 1;33(9):2266–75. - PMC - PubMed
    1. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is essential for the survival of long‐lived bone marrow plasma cells. J Exp Med. 2004. Jan 5;199(1):91–7. - PMC - PubMed
    1. Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, et al. Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012. Sep;158(6):727–38. - PubMed
    1. Cohen YC, Cohen AD, Delforge M, Hillengass J, Goldschmidt H, Weisel K, et al. Efficacy and safety of Ciltacabtagene Autoleucel (Cilta‐cel), a B‐cell maturation antigen (BCMA)‐directed chimeric antigen receptor (CAR) T‐cell therapy, in lenalidomide‐refractory patients with progressive multiple myeloma after 1‐3 prior lines of therapy: updated results from CARTITUDE‐2. Blood. 2021. Nov 23;138(Suppl 1):3866–6.
    1. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B‐cell maturation antigen‐directed chimeric antigen receptor T‐cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE‐1): a phase 1b/2 open‐label study. Lancet. 2021. Jul 24;398(10297):314–24. - PubMed

Publication types

Substances

Grants and funding